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Objectives We sought to evaluate placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) as clinical
biomarkers in chronic heart failure (HF).
Background Vascular remodeling is a crucial compensatory mechanism in chronic HF. The angiogenic ligand PlGF and its
target receptor fms-like tyrosine kinase 1 modulate vascular growth and function, but their relevance in human
HF is undefined.
Methods We measured plasma PlGF and sFlt-1 in 1,403 patients from the Penn Heart Failure Study, a multicenter cohort
of chronic systolic HF. Subjects were followed for death, cardiac transplantation, or ventricular assist device
placement over a median follow-up of 2 years.
Results The sFlt-1 was independently associated with measures of HF severity, including New York Heart Association
functional class (p  0.01) and B-type natriuretic peptide (p  0.01). Patients in the 4th quartile of sFlt-1 (379
pg/ml) had a 6.17-fold increased risk of adverse outcomes (p  0.01). This association was robust, even after
adjustment for the Seattle Failure Model (hazard ratio: 2.54, 95% confidence interval [CI]: 1.76 to 2.27, p 
0.01) and clinical confounders including HF etiology (hazard ratio: 1.67, 95% CI: 1.06 to 2.63, p  0.03). Com-
bined assessment of sFlt-1 and B-type natriuretic peptide exhibited high predictive accuracy at 1 year (area un-
der the receiver-operator characteristic curve: 0.791, 95% CI: 0.752 to 0.831) that was greater than either
marker alone (p  0.01 and p  0.03, respectively). In contrast, PlGF was not an independent marker of dis-
ease severity or outcomes.
Conclusions Our findings support a role for sFlt-1 in the biology of human HF. With additional study, circulating sFlt-1 might
emerge as a clinically useful biomarker to assess the influence of vascular remodeling on clinical outcomes.
(J Am Coll Cardiol 2011;58:386–94) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.032Although heart failure (HF) is primarily a disorder of the
myocardium, abnormal vascular function has a major
impact on HF progression and cardiac remodeling (1,2).
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July 19, 2011:386–94 Soluble Flt-1 in Chronic HFfunction and impaired revascularization (5). Even in the
setting of nonischemic heart disease, angiogenic factors
regulate myocardial capillary density as the heart hyper-
trophies (6,7), exert antiapoptoic and protrophic effects
in dilated cardiomyopathy (8), and influence peripheral
vascular load (9).
Placental growth factor (PlGF) is a member of the VEGF
family of angiogenic proteins and is expressed in placental,
cardiac, and lung tissue (10–12). Placental growth factor
activates the Fms-like tyrosine kinase receptor 1 (Flt-1) and
is expressed in numerous cell types, including endothelial
cells, monocytes, and renal mesangial cells. The Flt-1
receptor has affinity for PlGF, VEGF-A, and VEGF-B. In
animal models, these growth factors exert pleiotrophic
effects, including potentially beneficial effects, such as the
promotion of angiogenesis, and potentially harmful pro-
inflammatory effects, such as the promotion of atherogen-
esis (10–12). Hence, the overall effect of PlGF/Flt-1 sig-
naling in cardiovascular disorders might vary according to
disease state and comorbidities.
To better understand PlGF/Flt-1 signaling in the setting
of human disease, investigators have capitalized on the
observations that both PlGF and the circulating form of the
Flt-1 receptor—soluble Fms-like tyrosine kinase receptor 1
(sFlt-1)—can be easily quantified, providing a method to
conveniently gauge overall PlGF and sFlt-1 activity in
patients with cardiovascular disorders. During pregnancy,
changes in circulating PlGF and sFlt-1 reflect impaired
endothelial and glomerular function and predict preeclamp-
tic risk (13,14). In patients with chest pain and acute
coronary syndromes, higher PlGF levels are seen in those
with myocardial infarction (MI) and are associated with an
increased risk of short- and long-term adverse outcomes
(12,15,16). Studies of circulating sFlt-1 have demonstrated
conflicting results, with some studies noting higher levels
during acute MI compared with control patients (11) and
others noting lower plasma levels in patients during the
acute phase of MI compared with control subjects (17,18).
Although PlGF and sFlt-1 might be important disease
modifiers in chronic human HF, neither factor has been
comprehensively studied in this population. The largest
published experience on PlGF was a cross-sectional study of
98 patients that showed a positive relationship between
PlGF levels and New York Heart Association (NYHA)
functional class in ischemic HF but not in nonischemic
disease (19). Circulating sFlt-1 has not been studied in
human HF.
The purpose of our study was to evaluate circulating
PlGF and sFlt-1 as clinical biomarkers in a multicenter
cohort of 1,403 ambulatory HF outpatients. Our goals were:
1) to determine the factors that independently affect base-
line levels of PlGF and sFlt-1 in chronic HF; and 2) to test
the hypotheses that PlGF and sFlt-1 predict the combined
outcome of ventricular assist device (VAD) placement,
cardiac transplantation, or death.Methods
Study population. The Penn
Heart Failure Study is a multi-
center prospective cohort study
of outpatients with primarily
chronic systolic HF recruited
from referral centers at the Uni-
versity of Pennsylvania (Phila-
delphia, Pennsylvania), Case
Western University (Cleveland,
Ohio), and the University of
Wisconsin (Madison, Wisconsin)
(20). The primary inclusion cri-
terion is a clinical diagnosis of
HF. Participants are excluded if
they have a noncardiac condition
resulting in an expected mortality
of 6 months, as judged by the
treating physician, or if they were
unable or unwilling to provide
informed consent.
At time of study entry, de-
tailed clinical data were obtained
with a standardized question-
naire administered to the patient
and physician, with verification
via medical records. Venous blood
samples were obtained at enroll-
ment, processed, and stored at 80°C until time of assay.
Follow-up events, including all-cause mortality, cardiac
transplantation, and VAD placement, were prospectively
ascertained every 6 months.
All participants provided written, informed consent, and
the Penn Heart Failure Study protocol was approved by
participating institutional review boards.
Biomarkers assays. All biomarkers were measured from
the same aliquot from a banked plasma sample that was
obtained at time of study entry. The PlGF and sFlt-1were
measured with prototype ARCHITECT immunoassays
(Abbott Laboratories, Abbott Park, Illinois). The sFlt-1
immunoassay measures both free and bound sFlt-1, with an
assay range of 15 to 50,000 pg/ml. The intra- and inter-
assay coefficients of variation (CV) ranged from 1.3% to
5.2% and 1.9% to 5.9%, respectively. The PlGF immuno-
assay measures the free and not bound PlGF-1 with
approximately 20% cross-reactivity with the PlGF-2 iso-
form, with an assay range from 1 to 1,500 pg/ml. The
intraassay and interassay CV ranged from 1.4% to 6.7% and
1.8% to 6.7%, respectively.
The B-type natriuretic peptide (BNP) was measured with
the ARCHITECT BNP chemiluminescent microparticle
immunoassay (Abbott Laboratories) as previously described
(21). The assay range was from 10 to 5,000 pg/ml. The
intraassay and interassay CV ranged from 0.9% to 5.6% and
Abbreviations
and Acronyms
AUC  area under the
receiver-operator
characteristic curve
BNP  B-type natriuretic
peptide
CI  confidence interval
CV  coefficients of
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glomerular filtration rate
HF  heart failure
HR  hazard ratio
MI  myocardial infarction
NYHA  New York Heart
Association
PlGF  placental growth
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Soluble Flt-1 in Chronic HF July 19, 2011:386–94Statistical methods. Baseline characteristics were sum-
marized for the entire cohort with standard descriptive
statistics. Independent determinants of sFlt-1 and PlGF
levels were ascertained with a multivariable linear regres-
sion model for each marker. Adjustment variables were
selected from a saturated model that included all variables
listed in Online Tables 2 and 3. The inclusion of
adjustment variables was based on a stepwise model-
selection procedure that chose the subset of variables that
minimized the Akaike information criterion. The follow-
ing variables were retained on the basis of clinical/
biological judgment, regardless of their impact on Akaike
information criterion: age, sex, race, NYHA functional
class, cardiomyopathy etiology, estimated glomerular fil-
tration rate (eGFR), and BNP.
Cox regression models were used to determine the
unadjusted association between sFlt-1 and PlGF and time
to the combined outcome of all-cause death, cardiac trans-
plantation, or VAD placement. Biomarkers were modeled
as continuous variables and according to quartiles. Adjusted
models included covariates on the basis of statistical evi-
dence for confounding and clinical judgment. Statistical
evidence was defined by a univariable association with the
combined outcome at a significance level 0.10 and a
10% change in the estimated regression coefficient for
each biomarker. Covariates that met these criteria were: age,
sex, race, NYHA functional class, history of hypertension,
history of diabetes, tobacco use, cardiomyopathy etiology,
cardiac resynchronization, defibrillator, angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker
use, aldosterone use, aspirin use, beta-blocker use,
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibi-
tor use, and body mass index. Age exhibited nonpropor-
tional hazards and was thus adjusted for with a time-varying
covariate, which was obtained by multiplying age by a linear
term for time. Adjustment for NYHA functional class was
achieved by stratifying the baseline hazard function.
Clinical judgment included the consideration of can-
didate mediators of the observed association between
biomarker and outcome on the basis of the known
biology of these vascular growth factors. We decided a
priori to not adjust for peripheral vascular disease, ejec-
tion fraction, pulse pressure, eGFR, and sodium, given
the concern that each of these measures might represent
causal pathway mediators of the association between
vascular growth factors and adverse outcomes. These
hypotheses were based upon the established biological
effects of sFlt-1 and PlGF on renal dysfunction, vascular
disease, and cardiac remodeling (7,8,22–26). We fit
additional multivariable models to comprehensively as-
sess the independence and predictive value of our ob-
served associations in the context of validated clinical
models by adjusting for the Seattle Heart Failure Model
score, a standard risk prediction algorithm in HF (27).
The joint effects of sFlt-1 and BNP were evaluated by
dividing the cohort into groups on the basis of the bmedian level of each marker. In addition, time-
dependent receiver-operator characteristic (ROC) curves
were used to compare the ability of ln-transformed sFlt-1
and BNP to classify patients with regard to death, cardiac
transplantation, or VAD placement at 1 year (28).
Confidence intervals (CIs) for the area under the
receiver-operator characteristic curve (AUC) were ob-
tained from 1,000 bootstrapped samples, and AUCs were
compared with Wald tests. All statistical analyses were
completed with R software (version 2.11.0, R Foundation
for Statistical Computing, Vienna, Austria), including
the MASS, survival, and survivalROC packages (29–32).
Results
Baseline characteristics. Biomarker data were available for
1,535 subjects. Twenty-four subjects whose sFlt-1 or PlGF
was greater than the 99th percentile were excluded a priori
from all analyses, given that the levels in these patients are
most likely to be indicative of the influence of non-HF
disease states (e.g., pregnancy, infection, inflammation,
lupus, recent surgery, or cancer) (13,33–38). Of these 24
patients, there were 6 without an identifiable non-HF cause
of highly elevated biomarker levels. Inclusion of these 6
patients did not substantially change the results. Of the
remaining 1,511 patients, complete data on all baseline
characteristics and outcomes were available for 1,403 (93%)
subjects. For each characteristic with any missing data, the
amount of missingness averaged 1.5% and was no more than
1.7%. Those patients with any missing data did not differ
systematically from the remainder of the cohort (Online
Table 1).
The clinical characteristics of the 1,403 patients with
complete data are shown in Table 1. The majority of the
patients were male (67%) and Caucasian (74%), with a
mean age across the cohort of 56 years. There were 423
patients (30%) with an ischemic cause of HF, 397 (28%)
patients with a history of diabetes, and 817 (58%) with a
history of hypertension.
Independent determinants of baseline sFlt-1 and PlGF
levels. Across the cohort, the distributions of sFlt-1 and
PlGF were approximately normal, with slightly heavier
positive tails than would be expected if their distributions
were truly normal. The sFlt-1 levels ranged from 115 to
2,012 pg/ml, with a mean  SD of 348  181 pg/ml. The
median level was 308 (interquartile range: 258 to 379)
pg/ml. The PlGF levels ranged from 0.7 to 42.3 pg/ml, with
a mean  SD of 19.4  6.2 pg/ml. The median level was
8.6 (interquartile range: 15.0 to 22.7) pg/ml.
To establish the independent determinants of either
iomarker, we first assessed the univariable associations
etween baseline levels of either biomarker and clinical
haracteristics (Table 1, Online Tables 2 and 3). Then we
sed multivariable models to determine clinical factors
hat independently influenced baseline levels of each
iomarker. African-American race, higher NYHA func-
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July 19, 2011:386–94 Soluble Flt-1 in Chronic HFtional class, hypercholesterolemia, and higher plasma
NP were each independently associated with higher levels of
Flt-1 (Table 2). Increasing age, aspirin use, beta blocker use,
igher eGFR, and sodium were each independently associ-
ted with lower levels of sFlt-1. Given the positive skew of
Flt-1, we considered a sensitivity analysis in which we
odeled ln-transformed sFlt-1 levels as the outcome rather
han the nontransformed levels. The direction and magni-
ude of independent associations with ln-transformed sFlt-1
Baseline Characteristics for the Entire Cohort and by sFlt-1 QuartilTable 1 Baseline Characteristics for the Entire Cohort and by s
Cohort
n  1,403
Quartile 1
n  351
Demographic characteristics
Age, yrs 56 14 53 14
Male 939 (67) 228 (65)
Race
Caucasian 1,034 (74) 310 (88)
African-American 320 (23) 30 (9)
Other 49 (3) 11 (3)
Medical history and risk factors
History of hypertension 817 (58) 165 (47)
History of diabetes 397 (28) 71 (20)
Any peripheral vascular disease 182 (13) 23 (7)
Tobacco use
Never 518 (37) 154 (44)
Current 129 (9) 26 (7)
Former 756 (54) 171 (49)
Hypercholesterolemia 887 (63) 201 (57)
HF characteristics
NYHA functional classification
I 227 (16) 94 (27)
II 649 (46) 189 (54)
III 421 (30) 63 (18)
IV 106 (8) 5 (1)
Ischemic HF 423 (30) 87 (25)
Ejection fraction, % 33 17 37 16
Cardiac resynchronization therapy 354 (25) 63 (18)
Defibrillator 593 (42) 105 (30)
Medication use
ACE inhibitors or ARBs 1,224 (87) 315 (90)
Aldosterone antagonists 477 (34) 103 (29)
Aspirin 762 (54) 190 (54)
Beta-blockers 1,225 (87) 309 (88)
Clinical measures
Body mass index, kg/m2 30 7 29 5
Pulse pressure, mm Hg 45 15 45 13
eGFR, ml/min/1.73 m2 69 25 77 21
Sodium, mEq/l 139 3 140 3
Biomarkers or clinical risk scores
BNP, pg/ml 175 (48–531) 57 (21–117)
sFlt-1, pg/ml 348 181 227 26
PlGF, pg/ml 19.4 6.2 18.0 4.9
SHFM score 0.07 1.0 0.60 0.8
Values are mean  SD, n (%), or median (interquartile range). Soluble Fms-like tyrosine kinase 1
symmetric continuous variables; Kruskal-Wallis test for nonsymmetric continuous variables; chi-s
ACE  angiotensin converting enzyme; ARB  angiotensin receptor blocker; BNP  B-type natr
ssociation; PlGF  placental growth factor; SHFM  Seattle Heart Failure Model.ere similar to those provided in Table 2, with the excep-tion that pulse pressure was independently associated with a
significant decrease in sFlt-1 levels (1.4% decrease in sFlt-
1/10-mm Hg increase in pulse pressure, p  0.01).
For PlGF, increasing age, male sex, history of diabetes,
higher pulse pressure, use of cardiac resynchronization, and
higher BNP were each associated with higher levels
(Table 3). African-American race, angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker use, and
higher eGFR were each associated with lower levels of
Quartiles
Quartile 2
n  353
Quartile 3
n  348
Quartile 4
n  351 p Value*
55 14 58 15 58 14 0.01
238 (67) 231 (66) 242 (69) 0.78
0.01
263 (75) 238 (68) 223 (64)
72 (20) 101 (29) 117 (33)
18 (5) 9 (3) 11 (3)
191 (54) 234 (67) 227 (65) 0.01
91 (26) 112 (32) 123 (35) 0.01
51 (14) 56 (16) 52 (15) 0.01
0.03
124 (35) 120 (34) 120 (34)
40 (11) 26 (7) 37 (11)
189 (54) 202 (58) 194 (55)
218 (62) 236 (68) 232 (66) 0.02
0.01
81 (23) 41 (12) 11 (3)
174 (49) 180 (52) 106 (30)
84 (24) 108 (31) 166 (47)
14 (4) 19 (5) 68 (19)
94 (27) 127 (36) 115 (33) 0.01
34 16 33 17 28 17 0.01
67 (19) 108 (31) 116 (33) 0.01
135 (38) 164 (47) 189 (54) 0.01
323 (92) 310 (89) 276 (79) 0.54
104 (29) 123 (35) 147 (42) 0.01
199 (56) 195 (56) 178 (51) 0.41
317 (90) 310 (89) 289 (82) 0.01
30 7 32 8 30 8 0.01
45 15 47 16 42 16 0.01
73 24 64 26 59 26 0.01
139 3 140 3 138 4 0.01
124 (39–282) 229 (80–520) 766 (250–1,295) 0.01
282 14 336 21 546 266
19.4 5.8 20.4 5.9 20.0 7.4 0.01
0.33 0.8 0.03 0.9 0.62 1.0 0.01
quartiles: 258; 258 to 308; 308 to 379, 379 pg/ml. *On the basis of analysis of variance for
r categorical variables.
eptide; eGFR  estimated glomerular filtration rate; HF  heart failure; NYHA  New York HeartesFlt-1
(sFlt-1)
quare foPlGF. Interestingly, ischemic etiology was not indepen-
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Soluble Flt-1 in Chronic HF July 19, 2011:386–94dently associated with either biomarker (p 0.36 for sFlt-1;
p  0.19 for PlGF). Comparing Tables 2 and 3, it is
pparent that sFlt-1 levels were associated more strongly
ith measures of HF severity (e.g., NYHA functional class,
NP), compared with PlGF.
Flt-1 is independently associated with adverse outcomes
n chronic HF. Over a median follow-up time of 2 years,
here were 175 deaths, 103 transplants, and 27 VADs
mplanted. In unadjusted Cox models comparing the 4th
ersus 1st quartile, those patients with a circulating sFlt-1
evel 379 pg/ml had a 6.17-fold increased risk of adverse
utcomes (p  0.01) (Table 4, Fig. 1A). After adjustment
or demographic data, HF characteristics, and clinical mea-
ures including BNP, this association was attenuated in
Independent Determinants of Baseline sFlt-1 LeTable 2 Independent Determinants of Basel
Differ
Demographic characteristics
Age (10-yr difference)
African-American (vs. Caucasian)
HF characteristics
NYHA functional classification
II (vs. I)
III (vs. I)
IV (vs. I)
Medical history and risk factors
Hypercholesterolemia (vs. none)
Medication use
Beta-blockers (vs. none)
Aspirin (vs. none)
Clinical measures
eGFR (10-ml/min/1.73 m2 difference)
Sodium (1-mEq/l difference)
BNP (multiplicative difference of 2)
*Beta coefficient from a multivariable linear regression model for sFlt
for categorical or continuous variables. The mean  SD of sFlt-1 was
CI  confidence interval; other abbreviations as in Table 1.
Independent Determinants of Baseline PlGF LevTable 3 Independent Determinants of Basel
Di
Demographic characteristics
Age (10-yr difference)
Male (vs. female)
African-American (vs. Caucasian)
Medical history and risk factors
History of diabetes (vs. none)
HF characteristics
Cardiac resynchronization therapy (vs. none)
Medication use
ACE inhibitors or ARBs (vs. none)
Clinical measures
Pulse pressure (10-mm Hg difference)
eGFR (10-ml/min/1.73 m2 difference)
BNP (multiplicative difference of 2)
*Beta coefficient from a multivariable linear regression model for PlGF
categorical or continuous variables. The mean  SD of PlGF was 19.4  6.2
Abbreviations as in Tables 1 and 2.agnitude but remained statistically significant (hazard
atio [HR]: 1.67, 95% CI: 1.06 to 2.63, p  0.03,
omparing 4th quartile with 1st quartile). After adjustment
or established clinical risk scores such as the Seattle Heart
ailure Model, this association was attenuated to a lesser
egree (HR: 2.54, 95% CI: 1.76 to 2.27, p  0.01). Similar
esults were obtained when sFlt-1 was modeled as a con-
inuous variable. In contrast, patients in the highest quartile
f PlGF (22.7 pg/ml) had only a 1.89-fold increased risk,
hich did not remain significant in adjusted models (Table 4,
ig. 1B). As in our cross-sectional analyses, these findings
upport a role for sFlt-1 as an independent biomarker of HF
everity, whereas PlGF had no independent associations
ith outcomes.
Flt-1 Levels
n sFlt-1* 95% CI p Value
9 (15 to0.66) 0.02
(49 to 91) 0.01
2 (17 to 32) 0.56
(26 to 80) 0.01
0 (180 to 250) 0.01
(1.0 to 40) 0.04
(55 to4.6) 0.02
(43 to6.3) 0.01
0 (8.8 to1.2) 0.01
1 (7.7 to2.6) 0.01
(13 to 21) 0.01
represents the difference in mean sFlt-1 (pg/ml) between each group
181 pg/ml.
lGF Levels
ce in PlGF* 95% CI p Value
0.57 (0.31 to 0.84) 0.01
0.98 (0.34 to 1.6) 0.01
3.0 (3.8 to2.3) 0.01
1.1 (0.40 to 1.8) 0.01
0.88 (0.17 to 1.6) 0.02
1.1 (2.0 to0.21) 0.02
0.43 (0.23 to 0.64) 0.01
0.26 (0.39 to0.11) 0.01
0.21 (0.065 to 0.35) 0.01
presents the difference in mean PlGF (pg/ml) between each group forvelsine s
ence i
7.
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July 19, 2011:386–94 Soluble Flt-1 in Chronic HFAssociations between vascular growth factors and out-
comes might differ on the basis of the underlying etiology of
HF, with prior published reports indicating increased rele-
vance in ischemic disease (11,19). To explore these possi-
bilities, we performed secondary analyses that included
interaction terms between biomarker levels (modeled con-
tinuously) and HF etiology (ischemic or nonischemic). In
contrast to previously published reports, there were no
significant interactions by HF etiology on the associations
between either marker and outcome in our adjusted models
(interaction p  0.18 for sFlt-1; p  0.41 for PlGF).
Combined use of sFlt-1 and BNP in predicting outcomes.
We explored the effects of joint assessment of sFlt-1 and the
clinically used biomarker BNP in predicting adverse out-
comes. There was a moderate correlation between levels of
sFlt-1 and BNP (R  0.54, p  0.01), and their combined
use was important in risk assessment (Table 5, Online Fig. 1).
Compared with the referent group of patients with levels of
both markers less than the median, patients with elevations
in both sFlt-1 and BNP had a markedly elevated risk—in
contrast with either marker alone—and this association
remained significant in multivariable adjusted models (HR:
2.87, 95% CI: 1.96 to 4.21, p  0.01). Furthermore, in the
Association of sFlt-1 and PlGF With Risk of All-CCardiac Transplan atio , or VAD PlacementTable 4 As oci i of sFlt-1 and PlGF WithCardiac Transplantation, or VAD Pla
sFlt-1
HR (95% CI)
Model 1
Quartile 1 Referent
Quartile 2 1.76 (1.16–2.66)
Quartile 3 2.21 (1.47–3.31)
Quartile 4 6.17 (4.30–8.86)
Per SD increase 1.46 (1.37–1.54)
Model 2
Quartile 1 Referent
Quartile 2 1.42 (0.93–2.19)
Quartile 3 1.53 (1.00–2.33)
Quartile 4 2.61 (1.72–3.96)
Per SD increase 1.19 (1.10–1.28)
Model 3
Quartile 1 Referent
Quartile 2 1.24 (0.81–1.90)
Quartile 3 1.16 (0.75–1.80)
Quartile 4 1.67 (1.06–2.63)
Per SD increase 1.14 (1.05–1.24)
Model 4
Quartile 1 Referent
Quartile 2 1.40 (0.93–2.13)
Quartile 3 1.36 (0.90–2.07)
Quartile 4 2.54 (1.76–2.27)
Per SD increase 1.26 (1.17–1.36)
Model 1: unadjusted. Model 2: adjusted for age, sex, race, NYHA functio
etiology, internal cardiac defibrillator, cardiac resynchronization ther
3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibit
covariates and log2-transformed BNP. Model 4: adjusted for SHFM sc
HR  hazard ratio; VAD  ventricular assist device; other abbreviatgroup of patients with high BNP levels, the combination of Ta high sFlt-1 level was associated with a 1.5- to 2-fold
increase in risk, compared with those patients with low
sFlt-1 levels (p  0.01 unadjusted, p  0.04 adjusted).
In ROC analysis at 1 year (Fig. 2), sFlt-1 and BNP in
combination (AUC: 0.791, 95% CI: 0.752 to 0.831) showed
greater accuracy in classifying patients who died or required
heart transplantation or VAD placement than sFlt-1 alone
(AUC: 0.735, 95% CI: 0.689 to 0.781, p  0.01) or BNP
lone (AUC: 0.766, 95% CI: 0.726 to 0.807, p  0.03).
hese findings illustrate an improved ability to discern
igh- and low-risk HF patients at 1 year with both sFlt-1
nd BNP, compared with BNP alone.
iscussion
e report the first comprehensive assessment of PlGF
nd sFlt-1 as biomarkers in chronic HF. Our results
ndicate that sFlt-1 is strongly associated with adverse
utcomes across a broad spectrum of disease, even after
djusting for existing standards such as the Seattle Heart
ailure Model and natriuretic peptide levels. Further-
ore, combined use of sFlt-1 and BNP might be superior
o classifying patient risk than either biomarker alone.
Death,of All-Cause Death,
ent
PlGF
Value HR (95% CI) p Value
Referent
0.01 0.83 (0.58–1.19) 0.31
0.01 1.06 (0.75–1.50) 0.76
0.01 1.89 (1.39–2.58) 0.01
0.01 1.31 (1.18–1.46) 0.01
Referent
0.10 0.84 (0.58–1.23) 0.38
0.05 0.93 (0.64–1.35) 0.71
0.01 1.39 (0.98–1.97) 0.07
0.01 1.10 (0.98–1.23) 0.10
Referent
0.33 0.93 (0.64–1.36) 0.72
0.50 0.94 (0.65–1.37) 0.76
0.03 1.36 (0.96–1.93) 0.08
0.01 1.11 (0.99–1.25) 0.05
Referent
0.11 0.72 (0.50–1.03) 0.07
0.14 0.76 (0.53–1.08) 0.12
0.01 1.04 (0.75–1.42) 0.83
0.01 1.05 (0.94–1.17) 0.44
ssification, history of diabetes, tobacco use, ischemic cardiomyopathy
E inhibitor/ARB use, aldosterone antagonist use, beta-blocker use,
body mass index, and clinical site. Model 3: adjusted for Model 2
in Tables 1 and 2.auseRi k
cem
p








nal cla
apy, AC
or use,hese findings support a role for sFlt-1 in the biology of
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Soluble Flt-1 in Chronic HF July 19, 2011:386–94human HF and suggest that, with additional study,
circulating sFlt-1 might emerge as a clinically useful
biomarker to assess the influence of vascular remodeling
on clinical outcomes. In contrast, we found no evidence
to support a role for circulating PlGF in chronic HF.
Studies in animal models suggest several potential mech-
anisms through which VEGF/Flt-1 signaling might modify
the severity and course of HF. Soluble Flt-1 opposes
angiogenesis by binding to and sequestering salutary VEGF
ligands in the circulation, resulting in endothelial dysfunc-
tion and vascular rarefaction that increases mechanical load
on the heart (39–41). Excess sFlt-1 might also increase
myocardial fibrosis and decrease myocardial capillary den-
sity, thereby directly affecting myocardial structure and
Number at risk
Year 0 1 2 3 4 5
351 317 277 228 136 39
353 286 182 133 67 19
348 264 151 105 50 15
351 210 96 62 36 12
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Quartile 1: sFlt-1 258 pg/ml
Quartile 2: 258 < sFlt-1 308 pg/ml
Quartile 3: 308 < sFlt-1 379 pg/ml
Quartile 4: sFlt-1 > 379 pg/ml
A
Figure 1 Transplant and VAD-Free Survival According to Levels
Kaplan-Meier plots illustrating the incidence of all-cause death, cardiac transplanta
to baseline quartiles of soluble Fms-like tyrosine kinase 1 (sFlt-1) (A) and placent
Joint Effects of sFlt-1 and BNP on Risk of All-CaCardiac Transplantation, or VAD PlacementTable 5 J int Effects f sFlt-1 nd BNP on RCardiac Transplantation, or VAD Pla
Un
sFlt-1* BNP* n HR (95% C
Low Low 482 Referent
High Low 219 1.44 (0.86–2.
Low High 219 2.78 (1.84–4.
High High 483 6.08 (4.36–8
*Low/high sFlt-1 defined as below/above median (308 pg/ml); low
covariates listed in Table 4, Model 2.
Abbreviations as in Tables 1, 2, and 4.function (7,26). Soluble Flt-1 also impairs glomerular func-
tion and might contribute to unfavorable cardiorenal inter-
actions. Exogenous administration of sFlt-1 to both preg-
nant and nonpregnant animals induces widespread endothelial
dysfunction, hypertension, and renal dysfunction (13,23).
We found that, consistent with these observations, sFlt-1
was independently associated with renal dysfunction (22).
Discerning which of the effects of sFlt-1 is responsible for
our observed clinical associations will require additional
laboratory work.
Of note, we found that sFlt-1 was significantly associated
with disease severity and clinical outcomes independent of
HF etiology. These results provide human data supporting
a role for angiogenic growth factors even in nonischemic
1 2 3 4 5
352 270 181 142 91 31
356 283 192 146 84 28
348 270 170 128 60 11
347 254 163 112 54 15
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Quartile 2: 15.0 < PlGF 18.6 pg/ml
Quartile 3: 18.6 < PlGF 22.7 pg/ml
Quartile 4: PlGF > 22.7 pg/ml
0
lt-1 and PlGF
or ventricular assist device (VAD) placement according
th factor (PlGF) (B) (p  0.01 by log-rank test for each panel).
eath,f All-Cause Death,
ent
ted Adjusted†
p Value HR (95% CI) p Value
Referent
0.16 1.21 (0.71–2.14) 0.48
0.01 1.99 (1.30–3.05) 0.01
0.01 2.87 (1.96–4.21) 0.01
NP defined as below/above median (175 pg/ml). †Adjusted for allB
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July 19, 2011:386–94 Soluble Flt-1 in Chronic HFdisease, which has been observed in animal models. For
example, Izumiya et al. (7) have shown that inhibiting
angiogenic factors in mice subjected to pressure overload
impair cardiac growth and accelerate the transition to HF.
Similarly, VEGF signaling maintains endothelial cell ho-
meostasis (2) and exerts anti-apoptotic effects in pacing-
induced cardiomyopathy (8). Taken together with our
findings, these results emphasize the importance of vascular
growth remodeling in diverse forms of HF.
Studies of sFlt-1 in other cardiovascular diseases have
associated elevated sFlt-1 with worse outcomes, consistent
with our findings in HF. Soluble Flt-1 is elevated in patients
with acute MI who subsequently develop HF (11) and in
pregnant patients who subsequently develop preeclampsia
(13,14). As noted in the preceding text, a plausible inter-
pretation of these observations is that increased sFlt-1
reflects an underlying pathogenic process that accelerates
endothelial dysfunction, renal dysfunction, vascular disease,
and adverse remodeling by sequestering VEGF and associ-
ated ligands. However, Kodama et al. (18) have shown
elevated sFlt-1 levels in response to atorvastatin treatment
in a post-infarction study, and in this setting, a serial
increase in sFlt-1 is associated with an improvement in left
ventricular function. These findings suggest that the rela-
tionship between circulating sFlt-1 and outcomes might be
complicated by the presence of acute ischemia and also by
pharmacological therapy with statins. Although the associ-
ations we identified in chronic HF were independent of
pharmacotherapies, we cannot comment on the impact of
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sFlt-1 (AUC = 0.735)
BNP (AUC = 0.766)
sFlt-1 + BNP (AUC = 0.791)
Figure 2 AUC for sFlt-1 and BNP at 1 Year
Area under the receiver-operator characteristic curves (AUC) comparing the abil-
ity of baseline soluble Fms-like tyrosine kinase 1 (sFlt-1) and B-type natriuretic
peptide (BNP) levels to classify patients who died or required heart transplanta-
tion or ventricular assist device (VAD) placement at 1 year (p  0.01 and p 
0.03, respectively, for AUC comparing sFlt-1 and BNP vs. sFlt-1 or BNP alone).acute ischemia, which was not present in our study.Although PlGF levels were associated with a variety of
clinical factors in our cohort, including higher levels in renal
dysfunction, hypertension, and diabetes, PlGF was not an
independent marker of HF severity or adverse outcomes in
adjusted models. This stands in contrast to other disease
phenotypes in which PlGF is a predictor of disease out-
comes, such as preeclampsia, acute coronary syndromes, and
cancer (12,13,16,42). Thus, PlGF might be more relevant
to disease states that are primarily vascular in etiology, with
no current data to support a role for PlGF as a marker of
risk in chronic HF.
Study limitations. The strong and independent associa-
tions among sFlt-1, NYHA functional class, and risk of
adverse outcomes observed in our study support sFlt-1 as an
HF biomarker, but whether sFlt-1 itself plays a causal role
in HF progression cannot be determined from our obser-
vational study. Intervention studies are necessary to rigor-
ously test this hypothesis and test the biological basis of our
findings. Although the assays used were of high quality, we
quantified biomarker levels from peripheral plasma, and
there might be differences according to sampling site (11).
Our results might also not be generalizable to populations of
acute HF but represent chronic HF patients in a tertiary
referral setting that includes a substantial representation of
more severe disease. We currently do not have complete
data on transplant urgency, exercise capacity, other bio-
markers such as troponin, or quantitative cardiac remodel-
ing data and as such are unable to determine the relationship
between these parameters and sFlt-1 or PlGF. Finally,
because this work is the first to assess the relevance of
circulating sFlt-1 in chronic human HF, additional studies
are necessary to validate this work and further define clinical
effectiveness (43,44).
Conclusions
sFlt-1 is robustly associated with adverse outcomes in
chronic HF, supporting a role for Flt-1 signaling in human
HF progression. With further study, assessment of sFlt-1
might emerge as a useful clinical biomarker to enhance our
ability to stratify patient risk above and beyond currently
used approaches.
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